MEDICLIN Reports Growth in 2023 with Optimistic 2024 Outlook

MEDICLIN AG, under the ticker MED and WKN 659 510, announced its 2023 financial results, revealing a 3.6% increase in group sales reaching EUR 730.1 million. Despite the industry's challenges, the company has a positive projection for 2024, emphasizing its commitment to becoming a leading rehabilitation provider in Germany.

In the post-acute segment, MEDICLIN saw a 4.6% rise in sales to EUR 451.2 million. This segment, however, faced a downturn with a decreased operating result of EUR 12.7 million, falling by EUR 6.8 million from the previous year, primarily attributed to a one-off effect. Meanwhile, the acute segment experienced a modest growth of 0.5%, with sales amounting to EUR 254.0 million.

The company's strategic focus on outpatientization and digitalization of rehabilitation services has been central, alongside the expansion through the acquisition of a rehabilitation facility in Bremen. The nursing care business also showed progress, with sales increasing to EUR 21.3 million and turning a profit compared to the previous loss in the last year.

Looking ahead to 2024, MEDICLIN's management remains upbeat, expecting a sales growth of 3% to 5% and a Group EBIT forecast between EUR 38.0 million to EUR 46.0 million. The report highlights the stabilisation of occupancy rates as a positive indicator, despite not fully returning to pre-pandemic levels.